About Veklury Veklury remdesivir is a nucleotide analog with broad spectrum antiviral pastime both in vitro and in vivo in animal models against dissimilar rising viral pathogens. Multiple ongoing overseas Phase 3 medical trials are evaluating the protection and efficacy of remdesivir for the treatment of SARS CoV 2, the virus that causes COVID 19. In attention of the existing public health emergency and in keeping with accessible scientific data, remdesivir has been authorised as a cure for sufferers with severe COVID 19 in Japan, Taiwan, Hong Kong, India, Singapore, Australia, the United Arab Emirates and the European Union. Outside of these areas, remdesivir is an investigational, unapproved drug. Gilead Forward Looking Statement This press release carries ahead browsing statements, in the meaning of the Private Securities Litigation Reform Act of 1995, that are area to risks, uncertainties and other factors.
Remdesivir is an investigational drug that has not been accepted by the FDA for any use, adding for the cure of COVID 19. There is the probability of unfavourable outcomes from ongoing and extra scientific trials involving remdesivir and the opportunity that Gilead and other events may be unable to comprehensive a number of of such trials in the currently expected timelines or at all. Further, it is feasible that Gilead may make a strategic resolution to stop advancement of remdesivir or that FDA and other regulatory agencies won’t approve remdesivir, and any marketing approvals, if granted, may have significant limitations on its use. As a result, remdesivir may never be effectively commercialized. In addition, Gilead may face challenges associated with the allocation and geographical distribution of existing and future supply of remdesivir. If Gilead is unable to sufficiently scale up manufacturing of remdesivir in the presently expected timelines, Gilead may be unable to meet global supply needs.
These risks, uncertainties and other factors can cause actual results to differ materially from those cited in the ahead shopping statements. The reader is cautioned not to depend on these ahead browsing statements. These and other risks are defined intimately in Gilead’s Quarterly Report on Form 10 Q for the quarter ended March 31, 2020, as filed with the U. S. Securities and Exchange Commission. All ahead looking statements are in accordance with suggestions presently available to Gilead, and Gilead assumes no duty to update the sort of forward browsing statements.